Clinical Trials

Sponsor: Kronos Bio

Sponsor Study ID: KB-ENTO-3001

Study Title: Phase 3 trial using the SYK inhibitor, entospletinib, in combination with standard induction and consolidation chemotherapy in newly diagnosed, NPM1 mutated Acute Myelogenous Leukemia

NCT Number: NCT05020665

Phase: III

Protocol Type: Treatment

Age Group: Adult

Disease Sites: Myeloid and Monocytic Leukemia

Study Objectives: The primary objective of this study is to evaluate the efficacy of entospletinib (ENTO) compared to placebo when added to chemotherapy in previously untreated nucleophosmin-1 mutated (NPM1-m) acute myeloid leukemia (AML), as defined by the rate of molecularly defined measurable residual disease (MRD).

For more information about the trial above please contact the study team:

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)